CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tourmaline Bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tourmaline Bio Inc
27 West 24th Street, Suite 702
Phone: (302) 636-5400p:302 636-5400 NEW YORK, NY  10010  United States Ticker: TRMLTRML

This company was Merged or Acquired on 10/19/2023.
This is a Subsidiary, click here for the Parent Company

Business Summary
Tourmaline Bio, Inc., formerly Talaris Therapeutics, Inc., is a late-stage clinical biotechnology company. The Company is engaged in developing transformative medicines that improve the lives of patients with life-altering immune diseases. The Company’s lead program, TOUR006, is an anti-interleukin-6 (IL-6) antibody that exhibits differentiated properties, including high binding affinity to IL-6 and a naturally long half-life. TOUR006 selectively binds to IL-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory diseases. The Company focuses on developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional indications under consideration. TED is a debilitating autoimmune disorder. ASCVD is a group of disorders caused by plaque buildup and rupture in the artery walls and includes myocardial infarctions (heart attacks) and strokes.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Clay B.Siegall 63 12/13/2023 12/13/2023
Chief Executive Officer, Director SandeepKulkarni 10/19/2023 10/19/2023
Interim Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) RyanRobinson 10/19/2023 10/19/2023
9 additional Officers and Directors records available in full report.

Business Names
Business Name
TALS
Tourmaline Sub, Inc.
TRML

General Information
Number of Employees: 31 (As of 3/15/2024)
Outstanding Shares: 25,646,509 (As of 3/15/2024)
Shareholders: 20
Stock Exchange: NASD
Fax Number: (302) 636-5454
Email Address: info@talaristx.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024